1 Result: Longeveron
Longeveron's Lomecel-B shows promise for HLHS patients; Plug Power and Genius Sports report mixed Q1 earnings
May 09th, 2023
Longeveron Inc. (Nasdaq: LGVN) released new long-term follow-up data from its ELPIS I trial, highlighting the potential survival benefit of Lomecel-B for patients with hypoplastic left heart syndrome (HLHS). HLHS is a rare and life-threatening congen. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
Fluence Energy, Agilent Technologies, and Woodward Earnings On Deck: A Preview
November 24th, 2024Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024Key Metrics: CyberArk Software, Hudbay Minerals, and Sonos Earnings Due
November 11th, 2024Earnings: What to Expect from Occidental Petroleum, Rocket Lab, and CAE
November 10th, 2024Earnings Countdown: Home Depot, Sea Limited, and Natera in the Spotlight
November 10th, 2024
Member Login